Thursday, May 17, 2012

Potential new drugs for fox tapeworm infection in humans

Potential new drugs for fox tapeworm infection in humans [ Back to EurekAlert! ] Public release date: 16-May-2012
[ | E-mail | Share Share ]

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Scientists are reporting development and testing of a new series of drugs that could finally stop the fox tapeworm which causes a rare but life-threatening disease in humans dead in its tracks. The report, which appears in ACS' Journal of Medicinal Chemistry, shows that specific organometallic substances that help combat cancer are also the surprising best new hope for a treatment against tapeworm infection.

Carsten Vock, Andrew Hemphill and colleagues explain that alveolar echinococcosis (AE) is a parasitic disease caused by the fox tapeworm Echinococcus multilocularis. Although rare, AE disease results in the death of about 94 percent of patients worldwide within 10-20 years of diagnosis if not treated appropriately. Most infections occur in the Northern hemisphere, in places like central Asia, northwestern China, and parts of Japan and Europe. People become infected from eating food contaminated with the parasite's eggs, which are found in the feces of infected foxes, cats or dogs. Surgery is the best option for AE patients, but it does not always remove all of the parasites. Current AE drugs do not cure the disease, but simply keep the parasites at bay. These medicines must be taken life-long. In AE patients, the tapeworms cause tumor-like growths, which can metastasize or spread to different parts of the body. This reminded the researchers of cancer, so they looked at whether ruthenium complexes, promising anti-cancer agents, could also treat tapeworm.

The group prepared and evaluated several ruthenium complexes as potential drugs against the fox tapeworm. Some were effective in killing the tapeworms and also were less toxic on normal cells in laboratory dish tests, making them prime candidates for further development as treatments for AE.

###

The authors acknowledge funding from the Swiss National Science Foundation, the Bangerter Rhyner Foundation, the Swiss Life Foundation and Fondation Sana.

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society contact newsroom@acs.org.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Potential new drugs for fox tapeworm infection in humans [ Back to EurekAlert! ] Public release date: 16-May-2012
[ | E-mail | Share Share ]

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Scientists are reporting development and testing of a new series of drugs that could finally stop the fox tapeworm which causes a rare but life-threatening disease in humans dead in its tracks. The report, which appears in ACS' Journal of Medicinal Chemistry, shows that specific organometallic substances that help combat cancer are also the surprising best new hope for a treatment against tapeworm infection.

Carsten Vock, Andrew Hemphill and colleagues explain that alveolar echinococcosis (AE) is a parasitic disease caused by the fox tapeworm Echinococcus multilocularis. Although rare, AE disease results in the death of about 94 percent of patients worldwide within 10-20 years of diagnosis if not treated appropriately. Most infections occur in the Northern hemisphere, in places like central Asia, northwestern China, and parts of Japan and Europe. People become infected from eating food contaminated with the parasite's eggs, which are found in the feces of infected foxes, cats or dogs. Surgery is the best option for AE patients, but it does not always remove all of the parasites. Current AE drugs do not cure the disease, but simply keep the parasites at bay. These medicines must be taken life-long. In AE patients, the tapeworms cause tumor-like growths, which can metastasize or spread to different parts of the body. This reminded the researchers of cancer, so they looked at whether ruthenium complexes, promising anti-cancer agents, could also treat tapeworm.

The group prepared and evaluated several ruthenium complexes as potential drugs against the fox tapeworm. Some were effective in killing the tapeworms and also were less toxic on normal cells in laboratory dish tests, making them prime candidates for further development as treatments for AE.

###

The authors acknowledge funding from the Swiss National Science Foundation, the Bangerter Rhyner Foundation, the Swiss Life Foundation and Fondation Sana.

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society contact newsroom@acs.org.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


michael jordan checkers imbibe msg network ray j anthony shadid gary carter

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.